Ipca Labs gets USFDA EIR for Ratlam facility

Published On 2023-10-23 11:57 GMT   |   Update On 2023-10-23 11:57 GMT
Advertisement

Mumbai: Ipca labs has recently announced that the Company's manufacturing facility situated at Sejavata, Ratlam, Madhya Pradesh has received United States Food and Drug Administration (USFDA)'s Establishment Inspection Report (EIR) classifying the manufacturing facility as Voluntary Action Indicated (VAI).

USFDA had inspected the said facility from 5th June, 2023 to 13th June, 2023 and issued Form 483 with eleven observations.

Advertisement

Read also: USFDA issues 11 observations to Ipca Labs Ratlam facility

"We had vide our letter dated 14th June, 2023, intimated to you about US FDA inspection of Company’s APIs manufacturing facility situated at Sejavata, Ratlam, Madhya Pradesh from 5th June, 2023 to 13th June, 2023," the Company stated in a recent BSE filing.
"This manufacturing facility has now received Establishment Inspection Report classifying the manufacturing facility as “Voluntary Action Indicated (VAI) and that this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP)," the filing further stated.

Voluntary action indicated (VAI), which means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.

Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The Company was founded by group of businessmen and medical professionals in 1949. It produces theobromine, acetyl thiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally. Ipca is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.

Read also: Hitesh Kumar Maheshwari joins Ipca Labs as President - RnD (Formulations)

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News